# Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

> **NCT03542461** · PHASE3 · UNKNOWN · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 125 (actual)

## Conditions studied

- Squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab 10 MG/ML Intravenous Solution
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT03542461
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-25
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2022-10-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542461, "Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT03542461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*